التفاصيل البيبلوغرافية
| العنوان: |
Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2-4 preventives were not useful: results from the LIBERTY study. |
| المؤلفون: |
Lanteri-Minet, Michel, Goadsby, Peter J., Reuter, Uwe, Shihua Wen, Hours-Zesiger, Peggy, Ferrari, Michel D., Klatt, Jan, Wen, Shihua |
| المصدر: |
Journal of Neurology, Neurosurgery & Psychiatry; May2021, Vol. 92 Issue 5, p466-472, 7p |
| مصطلحات موضوعية: |
MIGRAINE aura, MIGRAINE, CALCITONIN gene-related peptide, PROPRANOLOL, THERAPEUTIC use of monoclonal antibodies, RESEARCH, RESEARCH methodology, MEDICAL cooperation, EVALUATION research, TREATMENT effectiveness, COMPARATIVE studies, REOPERATION, BLIND experiment |
| مستخلص: |
Objective: To evaluate the effect of erenumab on patient-reported, functional outcomes in patients with episodic migraine (EM) in whom 2-4 preventives were not useful from the Phase 3b LIBERTY study.Methods: As previously reported, 246 patients with EM with 2-4 prior failed preventives were randomised 1:1 to subcutaneous erenumab 140 mg or placebo every 4 weeks for 12 weeks. This analysis evaluated Migraine Physical Function Impact Diary (MPFID), Headache Impact Test (HIT-6) and Work Productivity and Activity Impairment (WPAI) scores at Week 12. P values were nominal without multiplicity adjustment.Results: Erenumab significantly improved MPFID-Physical Impairment (PI) and Everyday Activities (EA) scores versus placebo (treatment difference (TD) (95% CI) MPFID-PI: -3.5 (-5.7 to -1.2) (p=0.003); MPFID-EA: -3.9 (-6.1 to -1.7)) (p<0.001) at 12 weeks. Patients on erenumab were more likely to have a ≥5-point reduction in MPFID score (OR vs placebo (95% CI) MPFID-EA: 2.1 (1.2 to 3.6); MPFID-PI: 2.5 (1.4 to 4.5)). A similar trend was observed for HIT-6 (TD: -3.0; p<0.001); significantly higher proportions of patients on erenumab reported a ≥5-point reduction (OR (95% CI): 2.4 (1.4 to 4.1)). In three out of four WPAI domains, erenumab showed improvement versus placebo.Conclusion: At 12 weeks, erenumab was efficacious on functional outcomes in patients with EM in whom 2-4 preventives were not useful.Trial Registration Details: ClinicalTrials.gov identifier: NCT03096834. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Neurology, Neurosurgery & Psychiatry is the property of BMJ Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
